⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

Official Title: A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer

Study ID: NCT02083185

Conditions

Prostate Cancer

Study Description

Brief Summary: The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (\<50 ng/dL).

Detailed Description: The drug being tested in this study is called relugolix (TAK-385). Relugolix is being tested to treat people who have prostate cancer. This study will look at achieving and maintaining testosterone suppression (\<50 ng/dL). The study enrolled 136 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need): * Relugolix 80 mg * Relugolix 120 mg * Leuprorelin 22.5 mg Relugolix was administered starting with a 320 mg (loading dose), followed by relugolix 80 mg or 120 mg tablets, for 48 weeks plus an optional 48-week extension at the investigator's discretion. Patients randomized to leuprorelin were administered 22.5 mg subcutaneously on Day 1 and every 12 weeks for 4 injections. This multicenter trial was conducted in the United States and Canada. The overall time to participate in this study was 114.4 weeks. Participants made multiple visits to the clinic and at 12 weeks after last dose of study drug for a follow-up assessment.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

, Birmingham, Alabama, United States

, San Diego, California, United States

, Denver, Colorado, United States

, Daytona Beach, Florida, United States

, Jeffersonville, Indiana, United States

, Wichita, Kansas, United States

, Shreveport, Louisiana, United States

, Omaha, Nebraska, United States

, Lawrenceville, New Jersey, United States

, Garden City, New York, United States

, Syracuse, New York, United States

, Cincinnati, Ohio, United States

, Springfield, Oregon, United States

, Lancaster, Pennsylvania, United States

, Myrtle Beach, South Carolina, United States

, Nashville, Tennessee, United States

, Dallas, Texas, United States

, San Antonio, Texas, United States

, Virginia Beach, Virginia, United States

, Abbotsford, British Columbia, Canada

, Vancouver, British Columbia, Canada

, Montreal, Quebec, Canada

, Quebec, , Canada

Contact Details

Name: Medical Monitor

Affiliation: Millennium Pharmaceuticals, Inc.

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: